United States Glucose Monitoring Market Outlook to 2022

  • ID: 4031115
  • Report
  • Region: United States
  • 123 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Arkray Inc
  • Bayer HealthCare AG
  • Becton Dickinson and Co
  • DexCom Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
United States Glucose Monitoring Market Outlook to 2022

Summary

The author's new report, "United States Glucose Monitoring Market Outlook to 2022", provides key market data on the United States Glucose Monitoring market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Blood Glucose Meters, Blood Glucose Test Strips and Lancets.

The report also provides company shares and distribution shares data for each of these market segements, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size and company share data for Glucose Monitoring market segments - Blood Glucose Meters, Blood Glucose Test Strips and Lancets.
- Annualized market revenues (USD million) and volume (units) data for each of the market segements. Data is provided from 2008 to 2015 and forecast to 2022.
- 2015 company shares and distribution shares data for each of the market segements.
- Global corporate-level profiles of key companies operating within the United States Glucose Monitoring market.
- Key players covered include LifeScan Inc, Medtronic plc, Bayer HealthCare AG, F. Hoffmann-La Roche Ltd and Others.

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Arkray Inc
  • Bayer HealthCare AG
  • Becton Dickinson and Co
  • DexCom Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Glucose Monitoring Market Segmentation

2.3 Definitions of Markets Covered in the Report

3 Glucose Monitoring Market, United States

3.1 Glucose Monitoring Market, United States, Revenue ($m), 2008-2015

3.2 Glucose Monitoring Market, United States, Revenue ($m), 2015-2022

3.2.1 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2008-2015

3.2.2 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2015-2022

3.3 Glucose Monitoring Market, United States, Volume (Units), 2008-2015

3.4 Glucose Monitoring Market, United States, Volume (Units), 2015-2022

3.4.1 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2008-2015

3.4.2 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2015-2022

3.5 Glucose Monitoring Market, United States, Average Price ($), 2008-2022

3.6 Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), 2014-2015

3.7 Glucose Monitoring Market, United States, Company Share by Revenue ($m), 2015

4 Overview of Key Companies in United States, Glucose Monitoring Market

4.1 LifeScan Inc

4.1.1 Company Overview

4.2 Bayer HealthCare AG

4.2.1 Company Overview

4.3 Abbott Laboratories

4.3.1 Company Overview

4.4 DexCom Inc

4.4.1 Company Overview

4.5 F. Hoffmann-La Roche Ltd

4.5.1 Company Overview

4.6 Medtronic plc

4.6.1 Company Overview

4.7 Becton Dickinson and Co

4.7.1 Company Overview

4.8 Trividia Health Inc

4.8.1 Company Overview

4.9 Arkray Inc

4.9.1 Company Overview

5 Glucose Monitoring Market Pipeline Products

6 Financial Deals Landscape

6.1 Acquisition

6.1.1 BioTelemetry Acquires Telcare Medical Supply and Associated Assets

6.1.2 Abbott Labs to Acquire Alere

6.1.3 Teleflex Acquires Nostix

6.2 Debt Offerings

6.2.1 Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million

6.2.2 Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million

6.2.3 Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes

6.2.4 Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028

6.2.5 Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028

6.3 Partnerships

6.3.1 WellDoc Enters into Agreement with LifeScan

6.3.2 Diasend Partners with Abbott Labs

6.4 Venture Financing

6.4.1 Intuity Medical Raises USD40 Million in Series 3 Financing

6.4.2 Glooko Raises USD8 Million in Financing Round

6.4.3 Optiscan Biomedical Raises USD29.5 Million in Financing Round

6.4.4 GlySens Raises USD20 Million in Venture Financing

7 Recent Developments

7.1 Corporate Communications

7.1.1 Sep 20, 2016: Livongo Health Lands Dave Engberg from Evernote as Chief Technology Officer

7.1.2 Aug 16, 2016: One Drop Expands Diabetes Health and Behavioral Informatics Team With Addition of Chandra Osborn PhD, MPH as Vice President

7.1.3 Aug 02, 2016: PositiveID Adds GenArraytion CEO R. Paul Schaudies, Ph.D. to its Board of Advisors

7.1.4 Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures

7.1.5 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors

7.1.6 Jun 28, 2016: WellDoc, a Digital Health Technology Leader, Expands Leadership Team with Roster of Seasoned Healthcare Executives

7.1.7 Jun 22, 2016: Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations

7.1.8 Mar 23, 2016: GlucoTrack Maker Names Two New Board Members

7.1.9 Feb 26, 2016: Clinical Update On Thetanix For The Treatment Of Paediatric Crohn Disease : 4D Pharma

7.1.10 Jan 28, 2016: LivaNova Receives Regulatory Approval in Japan for KORA 250

7.1.11 Jan 19, 2016: Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace

7.1.12 Jan 08, 2016: BioGaia’s subsidiary IBT has US IND open and Swedish CTA approved for clinical study

7.2 Financial Announcements

7.2.1 Nov 21, 2016: PositiveID Reports Revenue of $4.6 Million for First Nine Months of 2016, Up 70% from $2.7 Million for First Nine Months of 2015

7.2.2 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results

7.2.3 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance

7.2.4 Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent

7.2.5 Nov 01, 2016: DexCom Reports Third Quarter 2016 Financial Results

7.2.6 Oct 27, 2016: Thermo Fisher Scientific Reports Third Quarter 2016 Results

7.2.7 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results

7.2.8 Sep 27, 2016: PositiveID Announces Highlights for Third Quarter 2016

7.2.9 Sep 06, 2016: Alere Reports Second Quarter 2016 Financial Results

7.2.10 Aug 17, 2016: Alere Reports First Quarter 2016 Financial Results

7.2.11 Aug 15, 2016: PositiveID Reports Q2 2016 Revenue of $1.8 Million, Up from $51 Thousand in Q2 2015

7.2.12 Aug 08, 2016: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2015 Financial Results

7.2.13 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter

7.2.14 Aug 03, 2016: Bio-Rad Reports Second-Quarter 2016 Financial Results

7.2.15 Aug 02, 2016: DexCom Reports Second Quarter 2016 Financial Results

7.2.16 Jul 28, 2016: Thermo Fisher Scientific Reports Second Quarter 2016 Results

7.2.17 Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results

7.2.18 Jul 12, 2016: PositiveID Announces Highlights for First Half of 2016

7.2.19 Jun 06, 2016: Sangui BioTech: Third Quarter Report

7.2.20 Jun 02, 2016: Fuel3D announces first enterprise client scanning solution

7.2.21 May 17, 2016: PositiveID Reports Q1 2016 Revenue of $1.7 Million, Up from $0.1M in Q1 2015

7.2.22 May 05, 2016: BD Announces Results For 2016 Second Fiscal Quarter

7.2.23 Apr 27, 2016: DexCom Reports First Quarter 2016 Financial Results

7.2.24 Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results

7.2.25 Apr 11, 2016: SteadyMed Announces Initiation Of Inter Partes Review Proceedings By U.S. Patent And Trademark Office Against A United Therapeutics Patent

7.2.26 Mar 10, 2016: Immunotherapeutic Potential of Manocept Platform Reviewed in the Journal Nuclear Medicine and Biology

7.2.27 Feb 23, 2016: DexCom Reports Fourth Quarter and Full Year 2015 Financial Results

7.2.28 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter

7.2.29 Jan 26, 2016: Johnson & Johnson Reports 2015 Fourth-Quarter Results

7.3 Legal And Regulatory

7.3.1 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm

7.3.2 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition

7.3.3 Aug 10, 2016: CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune Globulin

7.3.4 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic

7.3.5 Mar 21, 2016: LifeWatch: Supplemental information on Highmark arbitration case

7.3.6 Mar 17, 2016: LifeWatch announces arbitration decision in Highmark case

7.3.7 Mar 14, 2016: DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement

7.3.8 Feb 29, 2016: Baron & Budd Investigating Potential Lawsuits Against Johnson & Johnson Regarding Link Between Talcum Powder and Ovarian Cancer

7.4 Other Significant Developments

7.4.1 Dec 14, 2016: One Drop Announces Inaugural Members Of One Drop - Experts Advisory Board

7.4.2 Oct 20, 2016: Actor Derek Theler and Dexcom Take Center Stage to Raise Awareness of Diabetes

7.4.3 Aug 17, 2016: Livongo for Diabetes Program Generates Positive Clinical, Financial Outcomes

7.4.4 Jun 21, 2016: PositiveID’s Mobile Lab Business Completed 80 Projects in the First Half of 2016

7.4.5 May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-200 at Digestive Disease Week 2016

7.4.6 May 10, 2016: Thermo Fisher Scientific Reports Progress on Global Corporate Social Responsibility

7.4.7 May 03, 2016: Sentnyl Therapeutics, Re-Launches Abstral in the United States

7.4.8 Apr 06, 2016: Medtronic Statement on U.S. Department of Treasury's Recent Temporary and Proposed Regulations

7.5 Product News

7.5.1 Sep 12, 2016: Indiana University Research and Technology issued record 53 U.S. patents in 2015-16

7.5.2 Jun 28, 2016: Trividia Health Initiates Voluntary Recall of Certain Lots of TRUEread, TRUEbalance, TRUEtrack & TRUEtest blood glucose test strip

7.5.3 Apr 26, 2016: New Vigilant Diabetes Management Companion Launched in U.S. That Alerts Users to Risk of Severe Hypoglycemia in Next 24 Hours

7.5.4 Mar 09, 2016: Dexcom continuous glucose monitor receivers

7.6 Strategy And Business Planning

7.6.1 Nov 22, 2016: Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains

7.6.2 Nov 14, 2016: Diabetes Management Leader Dexcom Expands Presence in EMEA Markets with new Edinburgh HQ

7.6.3 Jun 20, 2016: Dexcom to Expand Manufacturing Operations to Greater Phoenix, Arizona

7.6.4 Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund

7.6.5 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges

8 Appendix

8.1 Research Methodology

8.1.1 Coverage

8.1.2 Secondary Research

8.1.3 Primary Research

8.1.4 Company Share Analysis

8.1.5 Distribution Share Analysis

8.1.6 Benchmarking

8.2 Consulting

8.3 Contact Us

8.4 Disclaimer

1.1 List of Tables

Table 1: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015

Table 2: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022

Table 3: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015

Table 4: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022

Table 5: Glucose Monitoring Market, United States, Volume (Units), Historic, 2008-2015

Table 6: Glucose Monitoring Market, United States, Volume (Units), Forecast, 2015-2022

Table 7: Blood Glucose Meters Market, United States, Volume (Units), Historic, 2008-2015

Table 8: Blood Glucose Meters Market, United States, Volume (Units), Forecast, 2015-2022

Table 9: Glucose Monitoring Market, United States, Average Price ($), Historic, 2008-2015

Table 10: Glucose Monitoring Market, United States, Average Price ($), Forecast, 2015-2022

Table 11: Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), USD Constant, 2014-2015

Table 12: Glucose Monitoring Market, United States, Company Share by Revenue ($m), USD Constant, 2015

Table 13: Glucose Monitoring Market Pipeline Products

Table 14: BioTelemetry Acquires Telcare Medical Supply and Associated Assets

Table 15: Abbott Labs to Acquire Alere

Table 16: Teleflex Acquires Nostix

Table 17: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million

Table 18: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million

Table 19: Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes

Table 20: Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028

Table 21: Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028

Table 22: WellDoc Enters into Agreement with LifeScan

Table 23: Diasend Partners with Abbott Labs

Table 24: Intuity Medical Raises USD40 Million in Series 3 Financing

Table 25: Glooko Raises USD8 Million in Financing Round

Table 26: Optiscan Biomedical Raises USD29.5 Million in Financing Round

Table 27: GlySens Raises USD20 Million in Venture Financing

1.2 List of Figures

Figure 1: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015

Figure 2: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022

Figure 3: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015

Figure 4: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022

Figure 5: Glucose Monitoring Market, United States, Volume (Units), Historic, 2008-2015

Figure 6: Glucose Monitoring Market, United States, Volume (Units), Forecast, 2015-2022

Figure 7: Blood Glucose Meters Market, United States, Volume (Units), Historic, 2008-2015

Figure 8: Blood Glucose Meters Market, United States, Volume (Units), Forecast, 2015-2022

Figure 9: Glucose Monitoring Market, United States, Company Share (%) 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- LifeScan Inc
- Bayer HealthCare AG
- Abbott Laboratories
- DexCom Inc
- F. Hoffmann-La Roche Ltd
- Medtronic plc
- Becton Dickinson and Co
- Trividia Health Inc
- Arkray Inc
<
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll